)
Cardiff Oncology (CRDF) investor relations material
Cardiff Oncology UBS Global Biopharma Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.First-line colorectal cancer opportunity and phase II findings
Onvansertib targets PLK1 in pan-RAS-mutated metastatic colorectal cancer; ~50% of patients have RAS mutations, and the speaker cited limited treatment innovation in this population over 20+ years.
In the randomized phase II CRDF-004 trial, onvansertib 30 mg plus FOLFOXIRI/bev showed ORR of 70%+ vs 42% with FOLFOXIRI/bev alone.
Median PFS was reached at ~11 months in the control arm but remained unreached with 30 mg onvansertib plus FOLFOXIRI/bev; the phase II study was small and not powered for PFS.
Tumor shrinkage and responses appeared durable; several patients in the 30 mg combination arm proceeded to curative surgery.
The 30 mg FOLFOXIRI/bev combination showed benefit trends across reported baseline subgroups; the speaker said this regimen had the strongest results and would advance to phase III.
Phase III and regulatory plans
FDA-aligned phase III plans compare onvansertib 30 mg plus FOLFOXIRI/bev with FOLFOXIRI/bev alone, enrolling patients across RAS mutations and powering the study for PFS and potential full approval.
The FDA will also allow ORR assessment for potential accelerated approval if results are compelling; Fast Track designation was announced shortly before the conference.
Trial initiation was targeted in a staged manner in Q1 2027, pending funding; a CRO had been selected, and regulatory work included manufacturing and companion diagnostic planning.
Cash was ~$34 million at Q3-end 2026, with expected runway through Q3 2027; European regulator feedback was awaited.
Other indications and pipeline
Relapsed/refractory CMML showed monotherapy activity, with responses cited at ~40%; an updated presentation was planned for the American Society of Hematology meeting in December 2026.
Orphan drug designations were received for CMML and small cell lung cancer; early monotherapy activity was also noted in small cell lung cancer.
- Phase 3 preparation advances as projected funding extends through Q3 2027.CRDF
Q3 2026 - A ~640-patient Phase III trial is planned for 1Q 2027, pending funding.CRDF
H.C. Wainwright 28th Annual Global Investment Conference - Vote to increase authorized shares aims to support future growth and financing flexibility.CRDF
Proxy filing - Shareholders will vote on a major increase in authorized shares at the October 2026 meeting.CRDF
Proxy filing - Vote sought to increase authorized shares and permit meeting adjournment if needed.CRDF
Proxy filing - Phase 2 success for onvansertib in mCRC; cash runway into Q3 2027, but litigation risk remains.CRDF
Q2 2026 - Onvansertib shows strong efficacy and safety in first-line RAS-mutated MCRC, with major updates due in Q1 2026.CRDF
Noble Capital Markets Emerging Growth Virtual Investor Conference - Advancing a well-tolerated PLK1 inhibitor to global phase III for RAS-mutated colorectal cancer.CRDF
Jefferies Global Healthcare Conference 2026 - 30 mg onvansertib plus FOLFIRI-BEV delivers 72.2% ORR and durable benefit in RAS-mutated mCRC.CRDF
Status update
)
)
)
)
)
)
)
)